Top Stories
Top Stories
Market Insider

After-hours buzz: JUNO, GPS, BMRN & more

Lucas Jackson | Reuters

Check out the companies making headlines after the bell Thursday:

Shares of Juno Therapeutics plunged after it announced that the Food and Drug Administration placed a hold on a phase 2 clinical trial of one of its products after two patients died last week.

The biopharmaceutical company focuses primarily on cancer treatment. The drug was being tested in adult patients with a type of relapsed leukemia.

AbbVie and Celgene, both biotechnology companies, also slightly dropped in sympathy.

Gap shares popped after the company reported better-than-expected same-store sales in June thanks in part to improved traffic at Old Navy. The retailer, known for its denim apparel, said net sales increased 2 percent to $1.57 billion during the month. Comparable sales rose 5 percent at Old Navy.

This time last year, comps fell 1 percent at the overall at the company and rose 1 percent at Old Navy, the company said.

"We are pleased to see better performance across the portfolio this month," chief financial officer Sabrina Simmons said in a statement.

BioMarin shares dipped in very light volume after hours, erasing some of the day's gains after a Betaville report said Swiss drugmaker Roche may be seeking to acquire it. The company, which focuses on rare diseases, could be sold for up to $130 to $150 per share, according to the report, which CNBC was unable to confirm.

Shares of Cimarex ticked higher after analysts raised price targets for the natural gas exploration and production company. Analysts at Canaccord Genuity recently raised their price target to $94 from $89, while Wunderlich Securities raised its target price to $176 from $139.

Oil prices fell roughly 5 percent on Thursday, closing at a near two-month low. Energy company SM Energy, though, popped after-hours.

Amid smaller stocks, Barracuda Networks spiked after the technology company reported quarterly sales that exceeded guidance. The cloud cybersecurity company posted earnings of 20 cents per share, adjusted, on revenue of $86.7 million, up 11 percent year-over-year.

"Our performance in the quarter was largely driven by execution on our strategy, which includes focusing our efforts to be the leader in security and data protection for our customers and expanding our routes to market, specifically in the MSP and public cloud channels," CEO BJ Jenkins said in a statement.

Anita Balakrishnan, Berkeley Lovelace Jr. and Reuters contributed to this story.